ORCHARD THERAPEUTICS NORTH AMERICA

Lobbying for ORCHARD THERAPEUTICS NORTH AMERICA · Health

Filing 1st Quarter - Amendment

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 29, 2026

Expenses

$470,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Government bodies contacted 5

Centers For Medicare and Medicaid Services (CMS)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 7871
MVP Act

Lobbying activity 2

Medicare/Medicaid

H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's

Health Issues

Accelerating Kids' Access to Care Act and Pediatric Priority Review Voucher (Give Kids a Chance Act) FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including HRSA Appropriations & Fundings; RUSP Conditions

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.